Saturday 17 October 2026
Export PYXS’s income statement to Excel — free account
Pyxis Oncology, Inc.
PYXS Healthcare Biotechnology
Pyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024. In the quarter to June 2026, EPS fell 33.3% and free cash flow fell 5.46%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.68
0.12
−6.67%
Follow PYXS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (179.10%) | (121.66%) | (91.43%) | (87.28%) |
+8 more TTM periods Free account |
|
| (99.62%) | (81.67%) | (64.03%) | (64.53%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(537.84%) | (223.45%) | (135.02%) | (134.56%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.06) | (1.06) | (1.02) | (1.16) | |
Free Cash Flow |
(67.91) | (66.97) | (63.51) | (72.37) | |
Capital Expenditures |
— | — | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(147.93%) | (90.79%) | (52.17%) | (49.40%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.02 | 0.02 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.82 | 0.80 | 0.75 | |
Depreciation/Fixed assets |
0.39 | 0.32 | 0.19 | (0.23) | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.06) | (1.06) | (1.02) | (1.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates